Weight loss medications work through several distinct biological pathways: some change how your brain registers hunger, others block fat absorption in your gut, and the newest class mimics hormones that regulate both appetite and blood sugar. The right medication depends on your starting weight, health conditions, and how your body responds. Here’s what each type actually does inside your body.
GLP-1 Medications: Mimicking Fullness Hormones
The most talked-about weight loss drugs right now, including semaglutide (sold as Wegovy) and liraglutide (Saxenda), belong to a class that copies a natural gut hormone called GLP-1. Your body releases this hormone after you eat, and it signals your brain’s satiety center that you’ve had enough food. These medications are synthetic versions of that hormone, engineered to last much longer in your body than the natural version does.
When you inject semaglutide once a week, it activates the same receptors in your brain that GLP-1 normally would, but it keeps them activated for days instead of minutes. The result is a persistent feeling of fullness and a reduced interest in food. Many people describe it as the “food noise” in their head going quiet. The effect on blood sugar is significant too: GLP-1 medications stimulate insulin release from the pancreas when blood sugar is high, which is why they were originally developed for type 2 diabetes.
These drugs also slow gastric emptying, meaning food sits in your stomach longer after a meal. That contributes to feeling satisfied sooner and for a longer stretch after eating. In clinical trials, a 68-week course of semaglutide at its highest dose reduced body weight by about 14.9% on average.
Dual Agonists: Two Hormones, Stronger Results
Tirzepatide (sold as Zepbound for weight loss) takes the GLP-1 approach a step further by also mimicking a second gut hormone called GIP. Both hormones regulate food intake by stimulating neurons in the brain’s satiety center, and both prompt the pancreas to release insulin. But they complement each other in important ways.
GIP directly stimulates fat storage in appropriate places (healthy fat tissue rather than around organs), while GLP-1 indirectly promotes fat breakdown. Together, they help maintain healthier fat cells, reduce dangerous fat deposits around organs, and increase production of adiponectin, a protein that improves how your body handles sugar and inflammation. Preclinical research showed that combining the two hormones produced greater weight loss and better blood sugar control than either one alone, and human trials confirmed the synergy. In a 72-week clinical trial, participants taking tirzepatide at its maximum dose lost an average of 20.2% of their body weight, about 50 pounds, compared with 13.7% (roughly 33 pounds) for those on semaglutide.
How These Injections Are Dosed
Both semaglutide and tirzepatide are given as weekly injections, and both start at low doses that gradually increase over several months. This slow ramp-up, called titration, is designed to let your body adjust and reduce side effects. Semaglutide starts at 0.25 mg per week and increases by 0.25 mg every four weeks, reaching the target dose of 2.4 mg within about 16 to 20 weeks. Tirzepatide starts at 2.5 mg and increases by 2.5 mg every four weeks, up to a maximum of 15 mg.
Not everyone needs the highest dose. Some people reach a dose where their appetite is well controlled and their weight is dropping steadily, and they stay there. Others need the full escalation to see meaningful results.
Oral Appetite Suppressants
Before the injectable hormone drugs arrived, the primary prescription options were oral medications that act on the brain’s appetite circuitry through different chemistry. One of the most prescribed is a combination of phentermine and topiramate, taken as a single daily pill.
Phentermine is a stimulant-like compound that triggers the release of norepinephrine in the hypothalamus, the brain region that controls hunger. This raises levels of leptin, a hormone that tells your body it has enough energy stored, which suppresses appetite. Topiramate was originally developed for seizures but turned out to have weight loss effects through several overlapping mechanisms: it boosts activity of a calming brain chemical called GABA, modifies how certain brain cells fire, and inhibits an enzyme involved in fat production. Neither drug’s weight loss mechanism is fully mapped out, likely because both affect multiple receptors at once. The combination uses lower doses of each drug than would be needed individually, which means fewer side effects than taking either at full strength.
Fat Absorption Blockers
Orlistat (available by prescription as Xenical and over the counter as Alli) works in an entirely different way. Instead of changing your appetite, it prevents your gut from absorbing some of the fat you eat. It does this by blocking lipase, the enzyme your digestive system uses to break down dietary fat. At the standard dose of 120 mg taken three times daily with meals, orlistat prevents about 30% of dietary fat from being absorbed. That undigested fat passes through your system and is excreted.
The weight loss from orlistat is more modest than what the injectable drugs produce, but it works through a purely mechanical process in the gut rather than affecting brain chemistry. The tradeoff is that eating high-fat meals while taking it can cause uncomfortable digestive symptoms, including oily stools, gas, and urgent bowel movements. Many people find that this side effect actually reinforces lower-fat eating habits.
Common Side Effects
The GLP-1 and dual agonist medications share a predictable set of gastrointestinal side effects, especially during the dose escalation period. Nausea is the most common, affecting roughly 21.5% of people taking semaglutide and about 25% of those on tirzepatide. Diarrhea occurs in about 10.6% of semaglutide users and 15% of tirzepatide users. Vomiting affects around 9% for both drugs. Constipation and indigestion each show up in about 8% of users.
For most people, these symptoms are worst in the first few weeks after each dose increase and then fade as the body adjusts. This is one reason the titration schedule is so gradual. Eating smaller meals, avoiding greasy or very rich foods, and staying hydrated all help manage the nausea during the adjustment period.
Who Qualifies for Prescription Treatment
Weight loss medications are not prescribed based on cosmetic goals. The standard criteria require that you’ve already tried to lose weight through diet and exercise without lasting success, and that your BMI is above 30 (the clinical threshold for obesity). If your BMI is above 27, you can also qualify if you have a weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol. These thresholds apply broadly across the prescription options, though insurance coverage varies widely by drug and plan.
What Happens When You Stop
One of the most important things to understand about these medications is that their effects depend on continued use. A systematic review published in The Lancet’s eClinicalMedicine found that within one year of stopping a GLP-1 medication, people regained about 60% of the weight they had lost during treatment. Beyond that first year, weight regain was estimated to plateau at roughly 75% of the lost weight.
This doesn’t mean the medications “didn’t work.” It reflects the biology of obesity: the hormonal signals that drive hunger and fat storage don’t reset permanently just because you lost weight. The medications override those signals while you’re taking them, but the underlying drive returns when treatment stops. For many people, this means weight loss medications are a long-term or even indefinite treatment, similar to blood pressure medication. Some clinicians are exploring whether lower maintenance doses can preserve results while reducing cost and side effects, but the pattern of regain after cessation is well established across studies.